{"Symbol": "APVO", "AssetType": "Common Stock", "Name": "Aptevo Therapeutics Inc", "Description": "Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.", "CIK": "1671584", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "2401 4TH AVENUE, SEATTLE, WA, UNITED STATES, 98121", "OfficialSite": "https://aptevotherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "10478200", "EBITDA": "-26468000", "PERatio": "0.0009", "PEGRatio": "0", "BookValue": "22.67", "DividendPerShare": "None", "DividendYield": "None", "EPS": "7758.2", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.792", "ReturnOnEquityTTM": "-2.427", "RevenueTTM": "0", "GrossProfitTTM": "345000", "DilutedEPSTTM": "7758.2", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-1", "AnalystTargetPrice": "378.0", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "1", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "0.0009", "ForwardPE": "3.945", "PriceToSalesRatioTTM": "1.607", "PriceToBookRatio": "0.396", "EVToRevenue": "0.122", "EVToEBITDA": "0.386", "Beta": "1.481", "52WeekHigh": "1439.96", "52WeekLow": "5.94", "50DayMovingAverage": "12.32", "200DayMovingAverage": "42.89", "SharesOutstanding": "1561600", "SharesFloat": "935440", "PercentInsiders": "0.076", "PercentInstitutions": "3.928", "DividendDate": "2020-03-27", "ExDividendDate": "None"}